. 2019 Aug 6;18(4):3501–3516. doi: 10.3892/ol.2019.10722

Table IV.

Association between the MAGE family members and different Pietenpol subtypes of patients with breast cancer.

MAGE family member	Affymetrix ID	Pietenpol subtype	HR	95% CI	P-value
MAGEA5	214642_at	Basal-like 1	0.60^a	0.37–0.96^a	0.0327^a
		Basal-like 2	1.71	0.84–3.46	0.1324
		Immunomodulatory	1.48	0.73–2.99	0.2723
		Mesenchymal	1.81^b	1.17–2.79^b	0.0066^b
		Mesenchymal stem-like	2.62	0.78–8.76	0.1041
		Luminal androgen receptor	0.62^a	0.41–0.93^a	0.0195^a
MAGEA8	210274_at	Basal-like 1	0.50^a	0.31–0.83^a	0.0059^a
		Basal-like 2	1.51	0.75–3.06	0.2499
		Immunomodulatory	1.36	0.71–2.61	0.3555
		Mesenchymal	0.60^a	0.38–0.95^a	0.0268^a
		Mesenchymal stem-like	0.41^a	0.18–0.93^a	0.0280^a
		Luminal androgen receptor	0.52^a	0.31–0.85^a	0.0076^a
MAGEB4	207580_at	Basal-like 1	0.60	0.36–1.02	0.0550
		Basal-like 2	2.74^b	1.22–6.14^b	0.0106^b
		Immunomodulatory	0.66	0.36–1.20	0.1708
		Mesenchymal	0.82	0.5–1.33	0.4204
		Mesenchymal stem-like	0.40	0.14–1.16	0.0794
		Luminal androgen receptor	0.64^a	0.41–1.00^a	0.0471^a
MAGEB6	1552858_at	Basal-like 1	0.64	0.31–1.33	0.2293
		Basal-like 2	0.43^a	0.19–0.97^a	0.0356^a
		Immunomodulatory	0.41^a	0.17–0.96^a	0.0333^a
		Mesenchymal	0.47^a	0.24–0.89^a	0.0181^a
		Mesenchymal stem-like	0.54	0.17–1.72	0.2907
		Luminal androgen receptor	0.58	0.33–1.02	0.0546
MAGEB18	1552913_at	Basal-like 1	1.75	0.90–3.40	0.0922
		Basal-like 2	0.51	0.22–1.18	0.1092
		Immunomodulatory	2.39^b	1.03–5.51^b	0.0353^b
		Mesenchymal	1.70	0.98–2.93	0.0543
		Mesenchymal stem-like	0.19^a	0.05–0.66^a	0.0039^a
		Luminal androgen receptor	2.04^b	1.11–3.77^b	0.0211^b
MAGEC3	216592_at	Basal-like 1	0.63	0.35–1.14	0.1255
		Basal-like 2	0.55	0.27–1.12	0.0933
		Immunomodulatory	0.69	0.35–1.37	0.2890
		Mesenchymal	0.65	0.43–1.00	0.0505
		Mesenchymal stem-like	0.32^a	0.12–0.85^a	0.0159^a
		Luminal androgen receptor	0.73	0.47–1.12	0.1508
MAGED2	213627_at	Basal-like 1	1.68^b	1.02–2.77^b	0.0386^b
		Basal-like 2	0.46^a	0.23–0.95^a	0.0308^a
		Immunomodulatory	1.34	0.72–2.49	0.3553
		Mesenchymal	1.43	0.83–2.46	0.1993
		Mesenchymal stem-like	0.60	0.27–1.32	0.2002
		Luminal androgen receptor	1.32	0.86–2.02	0.2000
MAGED3	205028_at	Basal-like 1	0.74	0.43–1.25	0.2584
		Basal-like 2	2.93^b	1.34–6.39^b	0.0047^b
		Immunomodulatory	1.46	0.80–2.65	0.2138
		Mesenchymal	1.59^b	1.04–2.43^b	0.0317^b
		Mesenchymal stem-like	2.06	0.92–4.63	0.0729
		Luminal androgen receptor	0.70	0.47–1.05	0.0839
MAGED4	221261_x_at	Basal-like 1	1.61^b	1.00–2.59^b	0.0494^b
		Basal-like 2	0.56	0.25–1.26	0.1558
		Immunomodulatory	0.64	0.34–1.18	0.1502
		Mesenchymal	0.80	0.51–1.26	0.3402
		Mesenchymal stem-like	3.16^b	0.94–10.56^b	0.0488^b
		Luminal androgen receptor	1.59^b	1.05–2.40^b	0.0267^b
MAGEE1	1556047_s_at	Basal-like 1	1.74	0.90–3.37	0.0980
		Basal-like 2	0.25^a	0.07–0.85^a	0.0160^a
		Immunomodulatory	0.41	0.12–1.37	0.1343
		Mesenchymal	1.82^b	1.06–3.15^b	0.0284^b
		Mesenchymal stem-like	0.41	0.15–1.13	0.0757
		Luminal androgen receptor	0.73	0.43–1.26	0.2576
MAGEE2	1553254_at	Basal-like 1	0.58	0.27–1.26	0.1636
		Basal-like 2	0.60	0.25–1.43	0.2440
		Immunomodulatory	1.91	0.82–4.41	0.1257
		Mesenchymal	0.72	0.39–1.30	0.2718
		Mesenchymal stem-like	0.34^a	0.12–0.97^a	0.0345^a
		Luminal androgen receptor	1.59	0.90–2.80	0.1067
MAGEF1	218176_at	Basal-like 1	0.75	0.46–1.23	0.2538
		Basal-like 2	0.33^a	0.14–0.81^a	0.0110^a
		Immunomodulatory	0.57	0.32–1.04	0.0623
		Mesenchymal	1.67	0.98–2.84	0.0573
		Mesenchymal stem-like	0.41^a	0.18–0.94^a	0.0292^a
		Luminal androgen receptor	0.61^a	0.41–0.91^a	0.0158^a
MAGEH1	218573_at	Basal-like 1	1.87^b	1.16–3.02^b	0.0090^b
		Basal-like 2	2.17^b	1.06–4.40^b	0.0288^b
		Immunomodulatory	1.89^b	1.05–3.42^b	0.0314^b
		Mesenchymal	1.56^b	1.01–2.42^b	0.0421^b
		Mesenchymal stem-like	0.56	0.23–1.36	0.1943
		Luminal androgen receptor	1.72^b	1.15–2.59^b	0.0079^b
MAGEL2	219894_at	Basal-like 1	1.55	0.96–2.49	0.0726
		Basal-like 2	0.55	0.25–1.20	0.1258
		Immunomodulatory	1.63	0.82–3.25	0.1574
		Mesenchymal	0.62^a	0.39–0.99^a	0.0433^a
		Mesenchymal stem-like	1.50	0.67–3.33	0.3206
		Luminal androgen receptor	0.61^a	0.41–0.93^a	0.0188^a

P<0.05 was considered to indicate a statistically significant difference.

High mRNA expression levels associated with improved RFS

high mRNA expression levels associated with worse RFS. Total patients assigned a Pietenpol subtype (31), n=1,246; patients with the basal-like 1 subtype, n=239; patients with the basal-like 2 subtype, n=97; patients with the immunomodulatory subtype, n=290; patients with the mesenchymal subtype, n=229; patients with the mesenchymal stem-like subtype, n=115; patients with the luminal androgen receptor subtype, n=276. CI, confidence interval; HR, hazard ratio; MAGE, melanoma-associated antigen.